

21th John Vane Memorial Symposium on Prostacyclin Science & Pulmonary Vascular Disease

Faculty Chair

Chris Thiernemann, Queen Mary University of London, UK

Session Chairs

Juergen Behr, Ludwig-Maximillan University, Munich, Germany

Athenais Boucly, Universite of Paris-Saclay, Paris, France

Michele D'Alto, Mondali Hospital, Naples, Italy

Ardeschir Ghofrani, University of Giessen, Giessen, Germany

Irene Lang, Medical University of Vienna, Vienna, Austria

Alan Lawrie, Imperial College London, London, UK

Vallerie McLaughlin, University of Michigan Health, Ann Arbor, MI, USA

Olivier Sitbon, Universite of Paris-Saclay, Paris, France

Marc Peters-Golden, University of Michigan, Ann Arbor, USA

Chris Thiernemann, Queen Mary University of London, London, UK

Jim White, University of Rochester, New York State, USA

Jason Weatherald, University of Alberta, Edmonton, Canada

Brendan Whittle, Queen Mary University of London, London, UK

13th and 14th March 2026

The Royal Society

6-9 Carlton House Terrace, London, SW1Y 5AG, UK

CPD approval TBC

Friday, 13th March 2026

08.30-09.20 Registration, tea and coffee

09.20 Welcome
Chris Thiernemann, Queen Mary University of London, UK

Session I

Chairs: *Chris Thiernemann, Queen Mary University of London, UK*
Brendan Whittle, Queen Mary University of London, UK

09.30 Final Frame: New concepts in end-of-life care
Hugh Montgomery, University College London, London, UK

10.00 Current challenges in emerging solutions in PH research
Ardeschir Ghofrani, University of Giessen, Giessen, Germany

10.30 Refreshments

Session II

Chairs: *Athenais Boucly, University of Paris-Saclay, Paris, France*
Alan Lawrie, Imperial College London, London, UK

11.00 New ways of patient stratification in PH: The plasma proteom
Athenais Boucly, University of Paris-Saclay, Paris, France

11.30 Diagnostic microRNA signatures to support classification of PH
Alan Lawrie, Imperial College London, London, UK

12.00 New imaging guidelines as a part of risk assessment and treatment algorithms in PH
Michele D'Alto, Mondali Hospital, Naples, Italy

12.30 Lunch

Session III

Chairs: *Michele D'Alto, Mondali Hospital, Naples, Italy*
Jason Weatherald, University of Alberta, Edmonton, Canada

14.00 Puffs, pills and pumps: Role of prostacyclins in 2026
Vallerie McLaughlin, University of Michigan Health, Ann Arbor, MI, USA

14.30 Novel mechanisms underlying the therapeutic effects of prostacyclins
Lucie Clapp, University College London, London, UK

15.00 Treating PH with interstitial lung disease
Vincent Cottin, Claude Bernard University of Lyon, Lyon, France

15.30 Refreshments

Session IV

Chairs: *Juergen Behr, Ludwig-Maximillian University, Munich, Germany*
Marc Peters-Golden, University of Michigan, Ann Arbor, MN, USA

16.00 Treatment of PH with pulmonary fibrosis
Juergen Behr, Ludwig-Maximillian University, Munich, Germany

16.30 Mechanism of the anti-fibrotic effects of prostaglandins
Marc Peters-Golden, University of Michigan, Ann Arbor, USA

17.00 Clinical and mechanistic insights into the therapeutic application of treprostinil in the treatment of pulmonary fibrosis
James May, Imperial College London, London, UK

17.30-18.30 Meeting Adjournment and Evening Reception at the Royal Society

Saturday, 14th March 2026

08.30 Tea and coffee

Session V

Chairs: *Vallerie McLaughlin, University of Michigan Health, Ann Arbor, MI, USA*
Olivier Sitbon, University of Paris-Saclay, Paris, France

09.00 Pulmonary vascular recruitment during exercise: A potential therapeutic endpoint in PAH and COPD
Jason Weatherald, University of Alberta, Edmonton, Canada

09.30 Remote measurements of efficacy in PH: a step towards decentralized clinical trials?
Jim White, University of Rochester, Rochester, NY, USA

10.00 Treatment options for early PH
Gabor Kovacs, University of Graz, Graz, Austria

10.30 Refreshments

Session VI

Chairs: *Irene Lang, University of Vienna, Vienna, Austria*
Jim White, University of Rochester, Rochester, NY, USA

11.00 Understanding the EXPEDITE study and its applicability in the current world
Vijay Balasubramanian, California Health Sciences University, CA, USA

11.30 Tyrosine kinase inhibitors and PAH: A double-edged sword?
Olivier Sitbon, University of Paris-Saclay, Paris, France

Session VII

Chairs: *Athenais Boucly, University of Paris-Saclay, Paris, France*
 Ardeschir Ghofrani, University of Giessen, Giessen, Germany
 Irene Lang, University of Vienna, Vienna, Austria
 Jim White, University of Rochester, Rochester, NY, USA

12.00 **Debate: Clinical trial design**

12.00 The US view!
 Vallerie McLaughlin, University of Michigan Health, Ann Arbor, MI, USA

12.20 The Canadian view!
 Jason Weatherald, University of Alberta, Edmonton, Canada

12.40 Discussion

13.00 Lunch

14.00 Close of meeting